Refine search

Tumour Site

83 results for ""

More needs to be done in renal cancer

More needs to be done in renal cancer

Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier  

On Target
Cancer Research

Colorectal cancer: guided by the gut?

Recent evidence suggests a role of the microbiome in cancer pathogenesis and as a potential therapeutic target, but it is still early days

By Elena Garralda
Public 4

What level of evidence do we need for drug approval in rare cancers?

Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy

Optimising clinical trials for greater inclusiveness

Optimising clinical trials for greater inclusiveness

Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.